Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII
Author:
Affiliation:
1. Bayer HealthCare Pharmaceuticals; Whippany NJ USA
2. Bayer Pharma AG; Wuppertal Germany
3. Bayer HealthCare; Berkeley CA USA
4. Israel National Hemophilia Center and Thrombosis Unit; Chaim Sheba Medical Centre; Tel-Hashomer Israel
Funder
Bayer HealthCare
Publisher
Wiley
Subject
Genetics(clinical),Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12691/fullpdf
Reference11 articles.
1. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management;Valentino;J Thromb Haemost,2012
2. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation;Kreuz;Thromb Haemost,2005
3. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study;Collins;J Thromb Haemost,2010
4. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group;Abshire;Thromb Haemost,2000
5. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation;Lusher;J Thromb Haemost,2004
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials;Journal of Blood Medicine;2023-06
2. Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation;Pharmacogenomics and Personalized Medicine;2023-03
3. Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A;Haemophilia;2022-11-29
4. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting;BMC Medical Research Methodology;2022-08-05
5. Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A;Thrombosis Research;2022-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3